University of British Columbia
Targeted delivery of toll-like receptor 7/8 agonists for the enhancement of cancer immunotherapy
Abstract
dc:descriptionSignificant advances in cancer immunotherapy have demonstrated the potential of harnessing the immune system to eradicate tumours. However, therapeutic efficacy is often limited by an immunosuppressive tumour microenvironment (TME) that inhibits anti-tumour immune responses. Toll-like receptor (TLR) agonists are potent immune stimulators capable of reprogramming the TME, but their poor solubility and risk of systemic toxicity present major barriers to clinical use. We hypothesized that nanoparticle-based delivery systems could improve the safety and efficacy of TLR agonists by enhancing tumour-targeted immune activation while minimizing off-target effects. This dissertation evaluated lipid-based nanoparticle formulations of the TLR agonists Resiquimod (R848) and Imiquimod (IMQ) in murine models of colorectal and ovarian peritoneal carcinomatosis and hepatocarcinoma. First, liposomal R848 was optimized in combination with oxaliplatin to identify treatment regimens that maximized therapeutic efficacy across multiple tumour models. Next, the mechanisms underlying treatment response were investigated, revealing coordinated changes in immune cell infiltration and metabolic pathways associated with effective anti-tumour immunity. 5-hydroxyindoleacetic acid and glucose-1,6-bisphosphate were identified as metabolites that were most abundantly different between Oxa only and Oxa+DSTAP-R848 treated groups. Finally, a phospholipid-free small unilamellar vesicle formulation was used to deliver IMQ to liver tumours, demonstrating anti-tumour activity and identifying gene expression signatures associated with treatment. Overall, nanoparticle-mediated delivery of TLR agonists enhanced anti-tumour responses across multiple murine cancer models while providing mechanistic insight into the immune and molecular changes associated with therapeutic success. These findings demonstrate the potential of nanomedicine platforms to improve the safety, precision, and effectiveness of immunomodulatory therapies and support their continued development as strategies to overcome current limitations in cancer immunotherapy.
Degree
thesis:*- Name thesis:degree_name
- Doctor of Philosophy - PhD
- Level thesis:degree_level
- doctoral
- Discipline thesis:degree_discipline
- Pharmaceutical Sciences
- Grantor dc:publisher
- University of British Columbia
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Chan, Vanessa
- Contributors dc:contributor
-
- Li, Shyh-Dar
Rights
dc:rights- Statement dc:rights
-
- Attribution-NonCommercial-NoDerivatives 4.0 International
- Language dc:language
- eng
Identifiers
dc:identifier.*- Handle dc:identifier
- http://hdl.handle.net/2429/95649